3/11
12:15 pm
spry
ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $19.00 price target on the stock.
Low
Report
ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $19.00 price target on the stock.
3/11
12:15 pm
spry
ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $19.00 price target on the stock.
Low
Report
ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $19.00 price target on the stock.
3/11
08:44 am
spry
Rating for SPRY
Low
Report
Rating for SPRY
3/11
08:44 am
spry
Rating for SPRY
Low
Report
Rating for SPRY
3/5
07:10 am
spry
Rating for SPRY
Low
Report
Rating for SPRY
2/21
05:43 pm
spry
ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $19.00 price target on the stock.
Medium
Report
ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $19.00 price target on the stock.
2/21
05:43 pm
spry
ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $19.00 price target on the stock.
Medium
Report
ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $19.00 price target on the stock.
2/20
12:11 pm
spry
ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) was upgraded by analysts at William Blair from a "market perform" rating to an "outperform" rating.
Low
Report
ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) was upgraded by analysts at William Blair from a "market perform" rating to an "outperform" rating.
2/20
12:11 pm
spry
ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) was upgraded by analysts at William Blair from a "market perform" rating to an "outperform" rating.
Low
Report
ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) was upgraded by analysts at William Blair from a "market perform" rating to an "outperform" rating.